NCT02163161View on ClinicalTrials.gov

AStudy to Evaluate the Bioavailability of PF 04965842 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

June 30, 2014

Primary Completion Date

August 31, 2014

Study Completion Date

August 31, 2014

Conditions
Healthy
Interventions
DRUG

PF-04965842

Subjects will receive 4 x 100 mg PF 04965842 tablet under fasted conditions

DRUG

PF-04965842

Subjects will receive 400 mg PF 04965842 oral suspension under fasted conditions

DRUG

PF- 04965842

Subjects will receive 4 x 100 mg PF 04965842 tablet under fed conditions

Trial Locations (1)

B-1070

Pfizer Investigational Site, Brussels

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY